- Home
- MVO vs PLUR Comparison
MVO vs PLUR Comparison
Compare MVO & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVO | PLUR |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 25.5M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | MVO | PLUR |
|---|---|---|
| Price | $1.52 | $2.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 144.8K | 13.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 17.46% | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | $1.08 | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $0.97 | $2.22 |
| 52 Week High | $6.26 | $5.96 |
Technical Indicators
Market Signals| Indicator | MVO | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 33.70 |
| Support Level | $1.33 | $2.22 |
| Resistance Level | $1.57 | $2.60 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 6.38 | 6.46 |
Price Performance
Historical ComparisonAbout MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. The trust was created to acquire and hold the net profits interest for the benefit of the Trust unitholders.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.